Mitsuaki Kawashima

Mitsuaki Kawashima

Auto-generated profile, based on publicly available information

Mitsuaki Kawashima

Department of Thoracic Surgery The University of Tokyo Tokyo Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
LLLiran Levy
Liran Levy
EHElla Huszti
Ella Huszti
BRBenjamin Renaud-Picard
Benjamin Renaud-Picard
GBGregory Berra
Gregory Berra
MKMitsuaki Kawashima
Mitsuaki Kawashima
TMTereza Martinu
Tereza Martinu

8 September 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
EAEtienne Abdelnour-Berchtold
Etienne Abdelnour-Berchtold
AAAadil Ali
Aadil Ali
CBCristina Baciu
Cristina Baciu
EBErika L. Beroncal
Erika L. Beroncal
AWAizhou Wang
Aizhou Wang
MCMarcelo Cypel
Marcelo Cypel

1 March 2020 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
MKMitsuaki Kawashima
Mitsuaki Kawashima
SJStephen Juvet
Stephen Juvet
Long-term survival after lung transplantation remains suboptimal due to chronic lung allograft dysfunction (CLAD), a progressive scarring process affecting the graft. Although anti-donor alloimmunity is central to the pathogenesis of CLAD, its underlying mechanisms are not fully elucidated and it is neither preventable nor treatable using currently available immunosuppression. Recent evidence has shown that innate immune stimuli are fundamental to the development of CLAD. Here, we examine long-standing assumptions and new concepts linking innate immune activation to late lung allograft fibrosis.

12 August 2015 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
MKMitsuaki Kawashima
Mitsuaki Kawashima
TMTomohiro Murakawa
Tomohiro Murakawa
TSTomohiro Shinozaki
Tomohiro Shinozaki
JIJunji Ichinose
Junji Ichinose
HHHaruaki Hino
Haruaki Hino
JNJun Nakajima
Jun Nakajima
OBJECTIVES The Glasgow Prognostic Score (GPS), which is calculated with C-reactive protein (CRP) and albumin (Alb) values, is a prognostic indicator for various types of cancers. However, its role in lung cancer still remains unclear, and its optimal cut-off values are controversial. Here, we evaluated the significance of the GPS and adjusted GPS (a-GPS) using our institution's cut-off values in patients undergoing resection for primary lung cancer. METHODS We analysed 1043 lung cancer patients who underwent resection between 1998 and 2012. The overall survival (OS) probabilities of the GPS subgroups were estimated using the Kaplan–Meier method and were compared using the log-rank test. The prognostic significance of the GPS and the a-GPS was assessed by the Cox proportional hazards model with clinicopathological variables and inflammation markers, such as the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR). The GPS was calculated based on cut-off values of 1.0 mg/dl for CRP and 3.5 g/dl for Alb, as previously reported. The a-GPS was calculated based on cut-off values 0.3 mg/dl for CRP and 3.9 g/dl for Alb, which are the standard thresholds used by our institution. RESULTS The GPS and the a-GPS were correlated with preoperative factors, such as age, sex, smoking status, the NLR and the PLR, and oncological factors, including the pathological stage, histological type and level of lymphovascular invasion. The 5-year OS rates were 82, 55 and 55% with GPS 0, 1 and 2 (1 vs 0: P < 0.01; 2 vs 1: P = 0.66), respectively, and 88, 67 and 59% with a-GPS 0, 1 and 2 (1 vs 0: P < 0.01; 2 vs 1: P = 0.04), respectively. Multivariable analysis revealed that the GPS [1 vs 0, hazard ratio (HR): 1.63, 2 vs 0, HR: 1.44] and the a-GPS (1 vs 0, HR: 2.00, 2 vs 0, HR: 2.10) were independent prognostic factors. The a-GPS classification showed a clearer prognostic distribution than the GPS classification. CONCLUSIONS The GPS is a useful prognostic indicator of the OS in lung cancer surgery. The optimal cut-off values for GPS estimation may need to be re-evaluated.

1 February 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
MKMitsuaki Kawashima
Mitsuaki Kawashima
JMJin Ma
Jin Ma
EHElla Huszti
Ella Huszti
LLLiran Levy
Liran Levy
GBGregory Berra
Gregory Berra
TMTereza Martinu
Tereza Martinu
While cytomegalovirus (CMV) viremia/DNAemia has been associated with reduced survival after lung transplantation, its association with chronic lung allograft dysfunction (CLAD) and its phenotypes is unclear. We hypothesized that, in a modern era of CMV prophylaxis, CMV DNAemia would still remain associated with death, but also represent a risk factor for CLAD and specifically restrictive allograft syndrome (RAS)/mixed phenotype. This was a single-center retrospective cohort study of all consecutive adult, first, bilateral-/single-lung transplants done 2010-2016, consisting of 668 patients. Risks for death/re-transplantation, CLAD, or RAS/mixed, were assessed by adjusted cause-specific Cox proportional-hazards models. CMV viral load (VL) was primarily modeled as a categorical variable: undetectable, detectable-999, 1000-9999, and ≧10000 IU/mL. In multivariable models, CMV VL was significantly associated with death/re-transplantation (≧10000 IU/mL: HR=2.65 (1.78-3.94), p<0.01), but was not associated with CLAD, whereas CMV serostatus mismatch was (D+R-: HR=2.04 (1.30-3.21), p<0.01). CMV VL was not associated with RAS/mixed in univariable analysis. Secondary analyses with a 7-level categorical or 4-level ordinal CMV VL confirmed similar results. In conclusion, CMV DNAemia is a significant risk factor for death/re-transplantation, but not for CLAD or RAS/mixed. CMV serostatus mismatch may have an impact on CLAD through a pathway independent of DNAemia.

2 February 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
TWTatsuaki Watanabe
Tatsuaki Watanabe
MKMitsuaki Kawashima
Mitsuaki Kawashima
MKMikihiro Kohno
Mikihiro Kohno
JYJonathan Yeung
Jonathan Yeung
James DownarJames Downar
James Downar
MCMarcelo Cypel
Marcelo Cypel
Over 2.5% of deaths in Canada occur as a result from Medical Assisting in Dying (MAID), and a subset of these deaths result in organ donation. However, detailed outcomes of lung transplant recipients using these donors is lacking. This is a retrospective single center cohort study comparing lung transplantation outcomes after donation using MAID donors compared to neurologically determined death and controlled donation after circulatory death (NDD/cDCD) donors from February 2018 to July 2021. Thirty-three patients received lungs from MAID donors, and 560 patients received lungs from NDD/cDCD donors. The donor diagnoses leading to MAID provision were: degenerative neurological diseases (n=33), and end stage organ failure (n=5). MAID donors were significantly older than NDD/cDCD donors [56 (IQR 49-64) years vs. 48 (32-59); P = .0009]. Median ventilation period and 30 days mortality were not significantly different between MAID and NDD/cDCD lungs recipients (ventilation: 1 day (1-3) vs 2 days (1-3); p=.37, deaths 0% (0/33) vs. 2% (11/560), p=.99 respectively). Intermediate-term outcomes were also similar. In summary, lung transplantation using donors after MAID, recipient outcomes are excellent. Therefore, where this practice is permitted, donation after MAID should be strongly considered for lung transplantation as a way to respect donor wishes while substantially improving outcomes for recipients with end-stage lung disease.